A new real-world study provides current data on the patterns for lines of therapy and treatment outcomes for DLBCL patients. This study looked at how doctors treat Diffuse Large B-cell lymphoma (DLBCL) in everyday practice, not just in clinical trials. It followed a large group of DLBCL patients for over 2 years to see what treatments they received and how they responded.
1,347 patients (with a median age of 67) were eligible for this study. Baseline characteristics, treatment patterns, and real-world outcomes were evaluated for the study population, including time to next treatment and overall survival, both overall and by line of therapy.
The most common first line of therapy for 63.6% of patients is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). More than 25% of people will require additional lines of treatment after their disease comes back (relapsed) or doesn't respond well (refractory). This number increases up for patients who needed a third or fourth round (3L or 4L).:
“As patients progressed from the first line of therapy to later lines of therapy, treatment patterns became more individualized.”
Outcomes are generally worse for patients who need later rounds of treatment: Patients who needed multiple rounds of treatment (especially 3L or 4L) tended to have lower survival rates and shorter time before their disease progressed again.
The study included a diverse patient population with variations in age, disease stage, prior treatments, and comorbidities across different lines of therapy. Overall, this study provides valuable real-world data on DLBCL treatment patterns and outcomes. It highlights the need for improved access to newer therapies and the development of even more effective treatments for patients with relapsed or refractory disease.
Stay up to date with all the treatment advances in your disease with Healthtree for DLBCL:
Sources:
A new real-world study provides current data on the patterns for lines of therapy and treatment outcomes for DLBCL patients. This study looked at how doctors treat Diffuse Large B-cell lymphoma (DLBCL) in everyday practice, not just in clinical trials. It followed a large group of DLBCL patients for over 2 years to see what treatments they received and how they responded.
1,347 patients (with a median age of 67) were eligible for this study. Baseline characteristics, treatment patterns, and real-world outcomes were evaluated for the study population, including time to next treatment and overall survival, both overall and by line of therapy.
The most common first line of therapy for 63.6% of patients is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). More than 25% of people will require additional lines of treatment after their disease comes back (relapsed) or doesn't respond well (refractory). This number increases up for patients who needed a third or fourth round (3L or 4L).:
“As patients progressed from the first line of therapy to later lines of therapy, treatment patterns became more individualized.”
Outcomes are generally worse for patients who need later rounds of treatment: Patients who needed multiple rounds of treatment (especially 3L or 4L) tended to have lower survival rates and shorter time before their disease progressed again.
The study included a diverse patient population with variations in age, disease stage, prior treatments, and comorbidities across different lines of therapy. Overall, this study provides valuable real-world data on DLBCL treatment patterns and outcomes. It highlights the need for improved access to newer therapies and the development of even more effective treatments for patients with relapsed or refractory disease.
Stay up to date with all the treatment advances in your disease with Healthtree for DLBCL:
Sources:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, a writer, and a HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.